Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n ¼ 33) or unrelated (n ¼ 18) donors. Twenty-seven patients, 19-54 years old, were prepared with myeloablative regimens including CY plus BU (n ¼ 4) or TBI (n ¼ 23). Twenty-four patients, 40-64 years old, received reduced-intensity conditioning (RIC) regimens. All RIC regimens contained fludarabine, combined with melphalan (n ¼ 19) or BU (n ¼ 5), and alemtuzumab or anti-thymocyte globulin (ATG) in the majority (n ¼ 19). Four patients (17%) in the RIC group had primary graft failure. Previous splenectomy reduced time to engraftment in the RIC group (13 versus 20 days; P ¼ 0.008). For MA and RIC groups, respectively, at 3 years, overall survival rates were 44 and 31% (P ¼ 0.67), progressionfree survival 44 and 24% (P ¼ 0.87), and actuarial relapse rates 15 and 46% (P ¼ 0.06). Non-relapse mortality at 3 years was 41% for the myeloablative and 32% for the RIC group. Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively. Extensive chronic GVHD developed in 30 and 35% of evaluable patients, respectively.
Introduction
Primary myelofibrosis (PMF) (myelofibrosis with myeloid metaplasia) is a clonal myeloproliferative disease that causes fibrosis of the bone marrow with resultant extramedullary haematopoiesis; splenomegaly and a leukoerythroblastic blood picture are characteristic features. 1, 2 Essential thrombocytosis and polycythaemia vera may also result in myelofibrosis that may be indistinguishable from PMF. The median survival is approximately 3-5 years. However, the International Working Group for Myelofibrosis Research and Treatment have recently devised a new prognostic scoring system with age greater than 65 years, presence of constitutional symptoms, haemoglobin level less than 10 g/dl, leukocyte count greater than 25 Â 10 9 /l, and circulating blast cells 1% or more as predictors of shortened survival. 3 Four risk groups were delineated based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or 3 or more (high risk) of these variables with respective median survivals of 135, 95, 48 and 27 months. The preceding prognostic scoring system of Dupriez et al. 4 identified three risk groups according to the presence of white cell count less than 4 Â 10 9 /l or greater than 30 Â 10 9 /l or anaemia (Hb o10 g per 100 ml) with median survival ranging from 93 months for score 0 (low risk), to 26 months for score 1 (intermediate risk) and 13 months for score 2 (high risk).
Conventional chemotherapy, corticosteroids, a-interferon and thalidomide have not been shown to prolong survival. [5] [6] [7] [8] Splenectomy is indicated in patients with symptoms related to splenomegaly, but the role of splenectomy before allogeneic transplantation is unclear. Although splenomegaly has been associated with prolonged time to engraftment, studies to date have not shown any consistent difference in transplantation outcomes in splenectomized patients 9, 10 and splenectomy in CIMF patients has been associated with a high rate of complications.
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Following the recent discovery of the V617F point mutation in JAK2 tyrosine kinase in the Philadelphianegative chronic myeloproliferative diseases including approximately 50% of PMF patients [12] [13] [14] [15] specific inhibitors of JAK2 kinase activity have been developed and are being evaluated in Phase 3 trials in PMF. 16 However, allogeneic SCT is currently the only curative treatment.
The use of conventional fully myeloablative (MA) conditioning regimens is associated with a high transplantation-related mortality (TRM) rate; [17] [18] [19] [20] [21] this is particularly seen in patients older than 45 years, 17 especially relevant given that PMF is most common in the middle-aged and elderly. Successful engraftment and disease remission have been shown using reduced-intensity conditioning (RIC) regimens in allogeneic SCT for PMF with apparently reduced TRM. [22] [23] [24] [25] [26] In contrast the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) recently reported a retrospective multicentre study of 100 patients, almost equally split between MA and RIC regimens, with no significant reduction in TRM in the RIC group. 27 We have performed a retrospective multicentre study of 51 patients prepared by conventional MA or RIC regimens for allogeneic haematopoietic SCT for CIMF in the United Kingdom between 1989 and 2005. Unlike the GITMO experience in this study most RIC regimens included T-cell depletion by alemtuzumab.
Patients and methods

Patients
Fifty-one patients with PMF who received an allogeneic stem cell transplant in the United Kingdom from 1989 to 2005 were analysed in this retrospective study. In all, 59 patients in 19 centres were identified in the BSBMT Data Registry, but eight patients from two centres were excluded from further analysis because the additional data required for the study was not provided. All of the patients met the WHO diagnostic criteria for PMF. Pre-transplant characteristics are summarized in Table 1 . Regrettably data are insufficient for calculation of the more recent International Working Group for Myelofibrosis Research and Treatment prognostic score for the majority of patients, and so Dupriez score has been assigned.
Donors
Stem cell source and histocompatibility results are summarized in Table 2 . For HLA-mismatched donors data is unavailable regarding degree of mismatch and loci involved. For unrelated donors HLA matched refers to 10/10 molecular match.
Transplantation
Transplant characteristics are summarized in Table 3 . All myeloablative conditioning regimens included CY, combined with TBI in the majority (23 patients) and BU in four cases; two patients whose donors were HLA-mismatched received fludarabine in addition to CY and TBI. The grafts for these two patients were T-cell depleted using alemtuzumab before infusion. Two patients in the CY/TBI group received alemtuzumab infusion as part of conditioning (the stem cell source was HLA-identical sibling for one patient and a matched unrelated donor for the other). All patients undergoing myeloablative conditioning received GVHD prophylaxis with CYA and methotrexate. All RIC regimens contained fludarabine, combined with melphalan in the majority (19 patients) and BU for the remaining five patients. The RIC conditioning regimen contained alemtuzumab (16 patients) or anti-thymocyte globulin (ATG)(-three patients) in most cases; in vitro T-cell depletion of the graft using alemtuzumab was performed in one of the remaining cases. Data regarding alemtuzumab dosage is incomplete. Only four patients received neither in vivo nor in vitro antibody-mediated T-cell depletion; these four patients received methotrexate in addition to CYA for GVHD prophylaxis.
Criteria for engraftment, response and GVHD The day of graft infusion was defined as day 0. The day of neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count of at least 0.5 Â 10 9 /l. Primary engraftment failure was diagnosed if the neutrophil engraftment end point was not reached by day 50. For patients receiving RIC regimens donor cell engraftment was documented by multi-lineage peripheral blood chimerism analysis using sex chromosome or DNA microsatellite analysis, although comprehensive chimerism data are not available for all patients. Haematological response was defined as complete (CHR) if all peripheral blood counts had normalized. CR was defined as the presence of normal peripheral blood counts, absence of splenomegaly and absence of bone marrow fibrosis.
Acute and chronic GVHD were graded according to standard criteria. 28, 29 Relapse was defined as the presence of the morphological criteria for myelofibrosis after initial clearance of the marrow.
The study period preceded the discovery of the JAK2V617F mutation. We therefore do not have data about JAK2 positivity or MRD data.
Statistical analysis
Comparisons between continuous variables (such as age) were made by Wilcoxon's rank-sum test. Categorical variables (such as splenectomy) were compared by Fisher's exact test. Overall and event-free survivals were calculated by the Kaplan-Meier method. Comparisons between survival outcomes were made by log-rank test, or by Cox regression for continuous variables. Non-relapse mortality was calculated by competing risks analysis, with death from relapse as the competing risk.
Results
Engraftment
In the myeloablative group, three patients died before day 20; all other patients engrafted. Four patients (17%) in the RIC group failed to achieve primary engraftment (one patient achieved neutrophil engraftment at day 120). Excluding these patients the median time to neutrophil engraftment was 18 days (range 8-35) for the myeloablative group and 17 days for the RIC group (range 10-35) (P ¼ 0.77). The patients who failed primary engraftment were equally divided between sibling-identical and matched unrelated donors. CD34 þ cell doses were 3.3, 3.6, 4.6 and 6.2 Â 10 6 /kg for those who failed engraftment, and all received PBSC. All received T-cell depletion during conditioning, with alemtuzumab in three cases and ATG in the remaining case. None of these patients had previous splenectomy. Of the patients who failed primary engraftment one went on to have a second transplant from the same donor; two patients died from infection and one received donor lymphocyte infusion (DLI) and was alive 1 year after transplantation. The median times to neutrophil engraftment were 14 (9-25), 17 (9-25), and 13 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ) days for splenectomized patients and 20 (8-35), 19.5 (8-35) , and 20 (14-35) days for those who had not had previous splenectomy in the total, MA and RIC groups, respectively. For the whole (P ¼ 0.008) and RIC (P ¼ 0.004) but not MA (P ¼ 0.333) groups previous splenectomy significantly reduced the time to engraftment in univariate analysis. Comprehensive chimerism data are not available.
GVHD
In all, 10 of 27 patients (37%) in the myeloablative group developed acute GVHD with 7 (29%) grades II to IV, 4 (15%) grades III to IV, and 3 (11%) of unknown grade. In the RIC group, nine patients (38%) developed acute GVHD grades II to IV and 3 (13%) grades III to IV. The 16 patients in the whole group who developed acute GVHD grade II to IV included 7 of 17 (41%) patients who had previous splenectomy and 9 of 21 (42%) who had not. Of 20 evaluable patients in the myeloablative group, five (25%) developed limited chronic GVHD, and six (30%) developed extensive chronic GVHD; data is unavailable for two patients. In the RIC group, of 17 evaluable patients, five (26%) patients developed limited and seven (37%) extensive chronic GVHD. Of the seven patients in the RIC group who developed extensive chronic GVHD three had received DLI for progressive disease, relapse or mixed chimerism.
Overall survival and progression-free survival (Post transplant disease status and relapse; toxicity and causes of death) Fourteen of the 27 patients (52%) in the myeloablative group died, seven (26%) within 100 days of transplant. Thirteen of the 24 patients (54%) in the RIC group died, five (21%) within 100 days of transplant. The causes of death are summarized in Table 4 . Intensity of conditioning regimen did not have a significant effect on NRM ( Figure 1) ; nor did donor type, patient sex, age, Dupriez score at transplantation, time from diagnosis to transplantation or previous splenectomy. Type of conditioning regimen did not have a significant effect on OS or PFS at 3 years with OS 44 and 31% (P ¼ 0.67), and PFS 44 and 24% (P ¼ 0.82) for MA and RIC groups, respectively. The increased relapse rate at 3 years for RIC regimens of 46% compared with 15% for myeloablative conditioning approached significance (P ¼ 0.06) (Figure 2 ). For the total group relapse rate was not significantly affected by Dupriez score at transplantation (P ¼ 0.84) or time from diagnosis to transplantation (P ¼ 0.98, comparing less than or greater than median time to transplantation). Nine (33%) of patients in the myeloablative group are alive in sustained at least haematological complete response (7 (26%) complete remission) at median follow up of 47 months (19-95 months); a further two patients had DLI for relapse and are alive at 45 and 90 months post-DLI; a further patient has achieved normalization of blood counts at 9 months post transplantation, but DLI is planned for mixed chimerism; information regarding response is missing for one patient alive 47 months post transplantation. Five patients (21%) in the RIC group are alive in sustained at least CHR (3 (12%) CR) at median follow up of 15 months (12-49 months); a further four (17%) patients are alive 7, 11, 11 and 40 (median 11 months) months post DLI for mixed chimerism or disease progression, and one is alive with planned DLI for mixed chimerism; one patient is alive 7 months following re-transplantation because of poor engraftment. Two patients in the RIC group received DLI, but died of relapse/progressive disease (one had extensive chronic GVHD).
Discussion
This retrospective study confirms the findings of previous reports that allogeneic SCT offers curative therapy for PMF. For the group of patients receiving myeloablative conditioning the overall survival (at 3 years) of 46% is comparable with that of 33-53% in previous reports of allogeneic haematopoietic SCT for PMF using myeloablative conditioning regimens. [17] [18] [19] [20] [21] The considerable nonrelapse mortality of 26% at 100 days and 41% at 2 years is also comparable with that of 27-48% in these reports. This transplant-related toxicity precluded allogeneic SCT for most patients with PMF, which most commonly presents in the seventh decade, until the introduction of RIC regimens with the potential reduction in TRM making allogeneic transplantation accessible to older patients and those with co-morbidities. Several smaller and two larger series (each of 21 patients) of RIC allogeneic transplantation for PMF showed engraftment, progression-free and overall survival rates not inferior to those reported for Non-relapse mortality rate by conditioning
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Cumulative incidence myeloablative preparation and showed reduction in TRM. [22] [23] [24] [25] [26] However, the recently published 20-year experience of allogeneic SCT in myelofibrosis of the GITMO, 27 a retrospective multicentre study of 100 patients, almost equally split between MA and RIC regimes, did not show any reduction in TRM (43% overall) or significant difference in transplantation outcomes for the RIC group. This study also failed to show any reduction in TRM in the RIC group with NRM at 2 years of 32%. OS and PFS in the RIC group (at 3 years) of 31 and 24% compare unfavourably with the outcomes of most previous reports as well as those of the contemporary myeloablative group. The relapse rate of patients receiving RIC regimens (46%) is increased compared with that of those prepared by myeloablative conditioning (15%), approaching significance (P ¼ 0.06). A third of the NRM resulted from failure of primary engraftment, four patients in this study failing to achieve primary engraftment as compared with none in the two larger series described. 25, 26 All of these patients had received G-CSF-mobilized PBSC with minimum CD34 þ cell dose 3.3 Â 10 6 /kg. It is of interest that none of these four patients were splenectomized. For the RIC group, although previous splenectomy did not have a significant effect on NRM, time to engraftment was significantly reduced for splenectomized patients (13 days (10-20) versus 20 days (14-35); P ¼ 0.004), but small numbers and univariate analysis limit the significance. Regrettably data regarding extent of splenomegaly are not available for all patients. Although there were more MUD donors in the RIC group, the NRM was not influenced by donor type.
Successful outcomes following RIC allogeneic transplant ation and responses to donor lymphocyte infusion suggest that myelofibrosis is responsive to donor T-cell alloantigen recognition eliciting a graft-versus-tumour effect. This may contribute to the progressive regression of bone marrow fibrosis that was complete by day 100 in 59%, day 180 in 90% and day 360 in 100% of patients in a recent analysis of RIC allogeneic transplantation for PMF. 30 Therefore, T-cell depletion, and in particular the use of alemtuzumab, given that ATG did not adversely affect engraftment or relapse rates in a previous report, 25 is a potential cause of the increased rates of relapse and primary graft failure in the current series. Unfortunately data regarding alemtuzumab doses is insufficient to assess possible effect of dosage on transplantation outcomes. Nevertheless, the increased rate of engraftment failure observed and the substantial relapse rate in the RIC group in the GITMO study in which alemtuzumab was not used and ATG administered only to recipients of MUD grafts suggests possible additional factors contributing to the adverse outcomes in the RIC group in our study.
In this study there was a significantly longer time from diagnosis to transplantation in the RIC group with a median time of 54 months (4-365 months) as opposed to 9.2 months (1-287 months) for the myeloablative group, but time from diagnosis did not have a significant effect on NRM or relapse rate for the group as a whole, and it has not been found to have an independent effect on transplantation outcomes in analyses of prognostic factors for allogeneic transplantation with conventional myeloablative conditioning. 17, 18 However, in the GITMO study shorter time from diagnosis to transplantation was favourably associated with outcome. As it seems reasonable that longer time from diagnosis to transplantation for CIMF may affect transplantation outcomes related to disease progression or patient's performance status, this merits further investigation, in particular because the risks of allogeneic transplantation mean that it is advised only for patients with intermediate to high-risk prognostic score. Unfortunately, data are incomplete regarding degree of pre-transplant bone marrow fibrosis in this study; this has previously been postulated to correlate with impaired engraftment. 19 However, 90% of patients in the series of Rondelli et al. 26 had grade III/IV marrow fibrosis (and only 14% were splenectomized), suggesting that increased severity of marrow fibrosis is unlikely to be the explanation for the engraftment failures in our series. Pre-transplantation Karnofsky performance stores are not available for all patients; however, age, Dupriez score and number and type of previous treatments are comparable with previous reports.
In previous studies of RIC transplantation for PMF rates of acute GVHD have appeared reduced compared with those reported for myeloablative conditioning, but have remained significant with chronic GVHD persisting as a major cause of transplant-related morbidity and mortality. In this study GVHD rates in the RIC group may have been influenced by the increased number of MUD donors, increased recipient age and increased use of PBSC. However, although the addition of alemtuzumab to conditioning regimens might be predicted to reduce GVHD incidence this is not apparent. Incidence of GVHD in the RIC group is not significantly different from that of the myeloablativeconditioning group, and is comparable with that previously reported for RIC regimens not including alemtuzumab. DLI is a contributory factor: three of seven (43%) evaluable patients who developed extensive chronic GVHD after RIC allogeneic transplantation had received DLI.
For younger patients for whom a choice between myeloablative and RIC preparation for allogeneic transplantation for PMF exists there is still some uncertainty given the relatively short follow-up of RIC regimens. This study is limited in that it is a multi-centre retrospective study performed over almost two decades and by numbers, but adds further difficulty; it appears that in the RIC setting choice of regimen and in particular T-cell modulation may be important factors in determining transplantation outcomes. Longer interval between diagnosis and transplantation may also adversely affect transplantation outcomes. As the only available curative option allogeneic transplantation is recommended for patients with PMF with intermediate to high risk prognostic scores, but RIC allogeneic transplantation should be within the context of a prospective clinical trial. In particular such a trial might address factors influencing engraftment including use and dose of alemtuzumab, higher stem cell doses and splenomegaly; the effect of T-cell modulation on relapse rate, whether this can be modified by DLI (guided by mixed chimerism or molecular monitoring in patients positive for JAK2 mutations); and effect of pre-transplantation prognostic score (assessed using the recently devised International Working Group for Myelofibrosis Research and Treatment score); and time from diagnosis on transplantation outcomes.
